← All drugs
Drug · FAERS side-effect profile with label screen

Citalopram side effects: what 136,022 FDA adverse event reports show

Citalopram · 1,167 reaction terms · 568,121 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Selective serotonin reuptake inhibitor (ssri)

FDA label, Indications wording

Who reports

136,022 reports · 77% serious · 18,996 with death outcome · 67% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Citalopram tablets are indicated for the treatment of major depressive disorder (MDD) in adults . Citalopram is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of major depressive disorder (MDD) in adults ( 1 ) .

FDA label, Indications and Usage

What it is

Citalopram tablets, USP contain citalopram, a selective serotonin reuptake inhibitor (SSRI). Citalopram hydrobromide is a racemic bicyclic phthalane structure and is designated (±)-1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3­dihydroisobenzofuran-5-carbonitrile hydrobromide with the following structural formula:

FDA label, Description section

Boxed warning

SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short- term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions ( 5.1 )] .

FDA label
How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled — boxed warning 3Labeled adverse reaction 3Labeled (related wording) 6Lab value / disease marker 3Outcome field, not a reaction 1Not in label — unassessed 24
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,127 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Temperature regulation disorder55652.5
47.7–57.8ROR 52.7 · calibrated p 1e-5 ✓
39.2 EB05 36.5 · IC025 +5.1
3/3 methods agree
Not in label — unassessedserious n=553 · ♀ 91% (drug 67%)no trial arm names this drug
Antipsychotic drug level below therapeutic17250.6
42.6–60.1ROR 50.6 · calibrated p 1e-5 ✓
38.0 EB05 33.5 · IC025 +4.9
3/3 methods agree
Lab value / disease markerserious n=171 · ♀ 0% (drug 67%) · 100% clinicianno trial arm names this drug
Agitation neonatal13024.2
20.1–29.1ROR 24.2 · calibrated p 9e-4 ✓
21.0 EB05 18.1 · IC025 +4.0
3/3 methods agree
Not in label — unassessedserious n=128 · ♀ 0% (drug 67%) · 100% clinicianno trial arm names this drug
Disinhibition21623.7
20.6–27.4ROR 23.8 · calibrated p 9e-4 ✓
20.6 EB05 18.4 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious n=216 · ♀ 0% (drug 67%)no trial arm names this drug
Respiratory disorder neonatal20422.6
19.5–26.1ROR 22.6 · calibrated p 0.001 ✓
19.7 EB05 17.6 · IC025 +4.0
3/3 methods agree
Not in label — unassessedserious n=204 · ♀ 0% (drug 67%)no trial arm names this drug
Catarrh10219.9
16.2–24.4ROR 19.9 · calibrated p 0.002 ✓
17.6 EB05 14.9 · IC025 +3.7
3/3 methods agree
Not in label — unassessedserious n=102 · ♀ 0% (drug 67%) · 100% clinicianno trial arm names this drug
Psychiatric decompensation19116.6
14.3–19.3ROR 16.7 · calibrated p 0.005 ✓
15.1 EB05 13.3 · IC025 +3.6
3/3 methods agree
Not in label — unassessedserious n=191 · ♀ 0% (drug 67%) · 100% clinicianno trial arm names this drug
Anorgasmia24415.1
13.2–17.2ROR 15.1 · calibrated p 0.007 ✓
13.8 EB05 12.4 · IC025 +3.5
3/3 methods agree
Labeled adverse reaction
exact term
serious n=229no trial arm names this drug
Accidental death15313.8
11.7–16.3ROR 13.8 · calibrated p 0.010 ✓
12.7 EB05 11.0 · IC025 +3.3
3/3 methods agree
Not in label — unassessedserious n=153 · 100% clinicianno trial arm names this drug
Food allergy60213.3
12.2–14.4ROR 13.3 · calibrated p 0.011 ✓
12.3 EB05 11.5 · IC025 +3.5
3/3 methods agree
Not in label — unassessedserious n=590 · ♀ 100% (drug 67%)no trial arm names this drug
Serotonin syndrome1,51313.2
12.5–13.9ROR 13.3 · calibrated p 0.011 ✓
12.2 EB05 11.7 · IC025 +3.5
3/3 methods agree
Labeled — boxed warning
exact term
age-adj. PRR 11.5 · serious PRR 9.1no trial arm names this drug
Tearfulness31211.9
10.6–13.4ROR 11.9 · calibrated p 0.017 ✓
11.1 EB05 10.1 · IC025 +3.3
3/3 methods agree
Not in label — unassessedserious n=288 · ♀ 43% (drug 67%)no trial arm names this drug
Alcohol poisoning18311.4
9.8–13.2ROR 11.4 · calibrated p 0.021 ✓
10.5 EB05 9.3 · IC025 +3.1
3/3 methods agree
Not in label — unassessedserious n=181 · ♀ 39% (drug 67%) · 100% clinicianno trial arm names this drug
Psychomotor skills impaired17210.7
9.2–12.5ROR 10.7 · calibrated p 0.026 ✓
10.0 EB05 8.8 · IC025 +3.0
3/3 methods agree
Not in label — unassessedserious n=171 · ♀ 0% (drug 67%) · 100% clinicianno trial arm names this drug
Burns second degree11310.6
8.7–12.8ROR 10.6 · calibrated p 0.028 ✓
9.8 EB05 8.3 · IC025 +2.9
3/3 methods agree
Not in label — unassessedserious n=111 · ♀ 0% (drug 67%) · 100% clinicianno trial arm names this drug
Nephrogenic anaemia2829.8
8.7–11.1ROR 9.9 · calibrated p 0.034 ✓
9.2 EB05 8.3 · IC025 +3.0
3/3 methods agree
Not in label — unassessedserious n=282no trial arm names this drug
Multiple drug overdose2959.5
8.5–10.7ROR 9.6 · calibrated p 0.038 ✓
9.0 EB05 8.1 · IC025 +3.0
3/3 methods agree
Not in label — unassessedserious n=294 · 100% clinicianno trial arm names this drug
Small for dates baby2879.4
8.3–10.5ROR 9.4 · calibrated p 0.041 ✓
8.8 EB05 8.0 · IC025 +2.9
3/3 methods agree
Not in label — unassessedserious n=287 · ♀ 47% (drug 67%)no trial arm names this drug
Long qt syndrome1389.3
7.8–11.1ROR 9.3 · calibrated p 0.042 ✓
8.7 EB05 7.5 · IC025 +2.8
3/3 methods agree
Labeled — boxed warning
exact term
serious n=137 · ♀ 100% (drug 67%) · 100% clinicianno trial arm names this drug
Multiple drug overdose intentional1839.1
7.8–10.6ROR 9.1 · calibrated p 0.045 ✓
8.5 EB05 7.5 · IC025 +2.8
3/3 methods agree
Not in label — unassessedserious n=182 · 100% clinicianno trial arm names this drug
Hyperparathyroidism secondary1429.1
7.7–10.8ROR 9.1 · calibrated p 0.045 ✓
8.5 EB05 7.4 · IC025 +2.8
3/3 methods agree
Not in label — unassessedserious n=142no trial arm names this drug
Blood pressure systolic abnormal1399.1
7.6–10.7ROR 9.1 · calibrated p 0.046 ✓
8.4 EB05 7.3 · IC025 +2.8
3/3 methods agree
Lab value / disease markerserious n=133 · ♀ 100% (drug 67%) · 100% clinicianno trial arm names this drug
Foetal death2899.0
8.0–10.2ROR 9.1 · calibrated p 0.046 ✓
8.5 EB05 7.7 · IC025 +2.9
3/3 methods agree
Not in label — unassessedserious n=289 · ♀ 100% (drug 67%) · 100% clinicianno trial arm names this drug
Hyperreflexia1918.8
7.6–10.2ROR 8.9 · calibrated p 0.049 ✓
8.3 EB05 7.3 · IC025 +2.8
3/3 methods agree
Labeled adverse reaction
exact term
serious n=188 · 100% clinicianno trial arm names this drug
Bruxism2948.8
7.8–9.9ROR 8.8 · calibrated p 0.049 ✓
8.3 EB05 7.5 · IC025 +2.9
3/3 methods agree
Not in label — unassessedserious n=265no trial arm names this drug
Completed suicide (death by suicide)4,4028.5
8.2–8.7ROR 8.7 · calibrated p 0.051
8.1 EB05 7.9 · IC025 +3.0
3/3 methods agree
Outcome field, not a reaction
boxed warning mentions mortality
age-adj. PRR 6.5 · serious PRR 6.0 · 94% clinicianno trial arm names this drug
Obsessive-compulsive disorder4118.2
7.4–9.1ROR 8.2 · calibrated p 0.061
7.8 EB05 7.2 · IC025 +2.8
3/3 methods agree
Not in label — unassessedserious n=380 · ♀ 37% (drug 67%)no trial arm names this drug
Torsade de pointes4008.2
7.4–9.1ROR 8.2 · calibrated p 0.061
7.8 EB05 7.2 · IC025 +2.8
3/3 methods agree
Labeled — boxed warning
exact term
serious PRR 5.8 · 100% clinicianno trial arm names this drug
Coeliac disease4968.2
7.5–8.9ROR 8.2 · calibrated p 0.063
7.7 EB05 7.2 · IC025 +2.8
3/3 methods agree
Not in label — unassessedserious PRR 7.1 · ♀ 100% (drug 67%)no trial arm names this drug
Blood pressure diastolic abnormal1298.1
6.8–9.7ROR 8.1 · calibrated p 0.066
7.6 EB05 6.5 · IC025 +2.6
3/3 methods agree
Lab value / disease markerserious n=125 · ♀ 100% (drug 67%) · 100% clinicianno trial arm names this drug
Tachyphrenia1707.9
6.8–9.2ROR 7.9 · calibrated p 0.070
7.4 EB05 6.5 · IC025 +2.6
3/3 methods agree
Not in label — unassessedserious n=135no trial arm names this drug
Bursitis5867.8
7.2–8.5ROR 7.9 · calibrated p 0.071
7.5 EB05 7.0 · IC025 +2.8
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 6.3 · ♀ 93% (drug 67%)no trial arm names this drug
Rebound acid hypersecretion1467.7
6.5–9.0ROR 7.7 · calibrated p 0.078
7.2 EB05 6.3 · IC025 +2.6
3/3 methods agree
Not in label — unassessedserious n=146no trial arm names this drug
Dyslipidaemia2367.5
6.5–8.5ROR 7.5 · calibrated p 0.083
7.1 EB05 6.3 · IC025 +2.6
3/3 methods agree
Not in label — unassessedserious n=229no trial arm names this drug

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Suicidality9,1615.95.8–6.1signal
Hyponatraemia2,2454.44.2–4.6signal
Depression6,3603.53.5–3.6signal
Extrapyramidal2,3073.43.3–3.6signal
Arrhythmia / qt3,5602.92.8–3.0signal
Fall / fracture6,0772.52.4–2.5signal
Gi bleeding2,4882.12.0–2.2signal
Seizure2,5042.01.9–2.1raised
Rhabdomyolysis / myopathy9801.91.8–2.0raised
Pancreatitis8991.71.6–1.8raised
Hypoglycaemia1,0201.61.5–1.8raised
Kidney injury4,7671.61.6–1.7raised
Anaemia3,0521.61.5–1.6raised
Venous thromboembolism2,1461.51.5–1.6raised
Serious infection7,3571.51.4–1.5raised
Liver injury2,8311.51.4–1.5raised

Trial evidence (ClinicalTrials.gov)

ClinicalTrials.gov returned results-bearing trials mentioning Citalopram only as a background or rescue medication (NCT01360866, NCT01838681); no trial listing it as the tested intervention was cached, so no trial cross-check is shown.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Fatigue (tiredness)9,1131.8
1.8–1.9ROR 1.9 · calibrated p 0.875
1.8 EB05 1.8 · IC025 +0.8Labeled adverse reaction
exact term
age-adj. PRR 1.6 · serious PRR 1.9no trial arm names this drug
Nausea8,3431.6
1.6–1.7ROR 1.7 · calibrated p 0.756
1.6 EB05 1.6 · IC025 +0.7Labeled adverse reaction
exact term
age-adj. PRR 1.4 · serious PRR 1.7no trial arm names this drug
Drug ineffective (drug did not work)7,4390.9
0.9–0.9ROR 0.9 · calibrated p 0.220
0.9 EB05 0.9 · IC025 -0.2
PRR-only: not supported by EBGM or IC
Reporting / coding artifactage-adj. PRR 0.9 · serious PRR 1.2no trial arm names this drug
Headache6,7921.7
1.6–1.7ROR 1.7 · calibrated p 0.779
1.7 EB05 1.6 · IC025 +0.7Labeled adverse reaction
exact term
age-adj. PRR 1.4 · serious PRR 1.9no trial arm names this drug
Diarrhoea (diarrhea)6,3481.5
1.5–1.6ROR 1.6 · calibrated p 0.676
1.5 EB05 1.5 · IC025 +0.6Labeled adverse reaction
exact term
age-adj. PRR 1.4 · serious PRR 1.4no trial arm names this drug
Pain6,0241.5
1.5–1.6ROR 1.5 · calibrated p 0.666
1.5 EB05 1.5 · IC025 +0.6Labeled adverse reaction
exact term
age-adj. PRR 1.5 · serious PRR 1.4no trial arm names this drug
Dizziness5,8121.8
1.8–1.9ROR 1.8 · calibrated p 0.856
1.8 EB05 1.8 · IC025 +0.8Labeled adverse reaction
exact term
age-adj. PRR 1.6 · serious PRR 1.9no trial arm names this drug
Fall5,7102.7
2.6–2.7ROR 2.8 · calibrated p 0.713
2.6 EB05 2.6 · IC025 +1.4
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.4 · serious PRR 2.1no trial arm names this drug
Anxiety5,5473.0
3.0–3.1ROR 3.1 · calibrated p 0.587
3.0 EB05 2.9 · IC025 +1.5
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.8 · serious PRR 2.8no trial arm names this drug
Dyspnoea (shortness of breath)5,4211.5
1.4–1.5ROR 1.5 · calibrated p 0.643
1.5 EB05 1.4 · IC025 +0.5Labeled adverse reaction
exact term
age-adj. PRR 1.3 · serious PRR 1.3no trial arm names this drug
Off label use (used outside approved label)5,3350.9
0.9–1.0ROR 0.9 · calibrated p 0.271
0.9 EB05 0.9 · IC025 -0.1
PRR-only: not supported by EBGM or IC
Reporting / coding artifactage-adj. PRR 0.9 · serious PRR 1.0no trial arm names this drug
Depression5,2753.6
3.5–3.7ROR 3.7 · calibrated p 0.433
3.6 EB05 3.5 · IC025 +1.8
3/3 methods agree
Labeled — boxed warning
synonym match
age-adj. PRR 3.2 · serious PRR 3.1no trial arm names this drug
Toxicity to various agents5,1914.9
4.8–5.0ROR 5.0 · calibrated p 0.230
4.8 EB05 4.7 · IC025 +2.2
3/3 methods agree
Not in label — unassessedage-adj. PRR 4.6 · serious PRR 3.6 · 93% clinicianno trial arm names this drug
Vomiting5,0621.7
1.6–1.7ROR 1.7 · calibrated p 0.768
1.7 EB05 1.6 · IC025 +0.7Labeled adverse reaction
exact term
age-adj. PRR 1.5 · serious PRR 1.5no trial arm names this drug
Drug interaction4,4474.4
4.3–4.5ROR 4.5 · calibrated p 0.292
4.3 EB05 4.2 · IC025 +2.1
3/3 methods agree
Reporting / coding artifactage-adj. PRR 3.9 · serious PRR 3.4no trial arm names this drug

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Citalopram ↔ QT prolongation.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Citalopram?

In FDA FAERS, the most frequently co-reported reaction terms for Citalopram are fatigue, nausea, headache, diarrhoea, pain, dizziness. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Citalopram have an FDA boxed warning?

Yes. The current FDA label carries a boxed warning: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short- term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions ( 5.1 )] .

Do FAERS signals prove that Citalopram causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.